Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2

B. D. Curti, D. L. Longo, A. C. Ochoa, K. C. Conlon, J. W. Smith, W. G. Alvord, S. P. Creekmore, R. G. Fenton, B. L. Gause, J. Holmlund, J. E. Janik, J. Ochoa, P. A. Rice, W. H. Sharfman, M. Sznol, W. J. Urba

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: This study describes the physiologic and biologic effects resulting from the adoptive transfer of ex vivo anti-CD3-stimulated T-killer cells (T-AK) to patients with advanced cancer in combination with interleukin-2 (IL-2). Methods: Autologous peripheral-blood mononuclear cells were obtained by leukapheresis and stimulated ex vivo with anti-CD3. The stimulated cells were reinfused at one of three dose levels on the next day (5 x 109, 7.5 x 109, and 1 x 1010). Cell administration was followed by IL-2 given by bolus and continuous infusion (1.5 x 106 U/m2 and 3.0 x 106 U/m2, respectively) for 7 days, or continuous infusion alone (3.0 x 106 U/m2) for 14 days. Results: Pronounced leukocytosis and atypical lymphocytosis were observed with individual values as high as 80,000 and 50,000 cells/μL, respectively. The other major clinical sequelae included a marked lactic acidosis with bicarbonate levels as low as 4.0 mmol/L in some patients, and prolongation of the prothrombin time (PT) and partial thromboplastin time (PTT) due to decreases in clotting factors VII, IX, and X. Antithrombin III levels were also reduced. Hypotension associated with increased serum nitrate and neopterin levels was observed. These toxicities were accompanied by increases in hepatocellular enzymes and creatinine previously described with IL-2. These events occurred at a time when the number of circulating T-AK cells reached their peak. The amount of bolus IL- 2 correlated with increases in WBC count (P = .0311), atypical lymphocytes (P = .0241), PT (P = .0006), and PTT (P = .0122). Conclusion: Substantial in vivo expansion of activated T lymphocytes was induced by a protocol combining ex vivo activation of peripheral-blood cells with anti-CD3 antibody followed by adoptive transfer and IL-2 administration. The synchronous expansion of these T cells superimposed on diminished liver and kidney function from IL-2 can cause profound but reversible metabolic changes.

Original languageEnglish (US)
Pages (from-to)652-660
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number4
DOIs
StatePublished - Jan 1 1993

Fingerprint

Interleukin-2
Neoplasms
Partial Thromboplastin Time
Adoptive Transfer
Prothrombin Time
Blood Cells
Therapeutics
Leukapheresis
Neopterin
T-Lymphocytes
Lymphocytosis
Factor X
Lactic Acidosis
Factor VII
Factor IX
Blood Coagulation Factors
Antithrombin III
Leukocytosis
Bicarbonates
Nitrates

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Curti, B. D., Longo, D. L., Ochoa, A. C., Conlon, K. C., Smith, J. W., Alvord, W. G., ... Urba, W. J. (1993). Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. Journal of Clinical Oncology, 11(4), 652-660. https://doi.org/10.1200/JCO.1993.11.4.652

Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. / Curti, B. D.; Longo, D. L.; Ochoa, A. C.; Conlon, K. C.; Smith, J. W.; Alvord, W. G.; Creekmore, S. P.; Fenton, R. G.; Gause, B. L.; Holmlund, J.; Janik, J. E.; Ochoa, J.; Rice, P. A.; Sharfman, W. H.; Sznol, M.; Urba, W. J.

In: Journal of Clinical Oncology, Vol. 11, No. 4, 01.01.1993, p. 652-660.

Research output: Contribution to journalArticle

Curti, BD, Longo, DL, Ochoa, AC, Conlon, KC, Smith, JW, Alvord, WG, Creekmore, SP, Fenton, RG, Gause, BL, Holmlund, J, Janik, JE, Ochoa, J, Rice, PA, Sharfman, WH, Sznol, M & Urba, WJ 1993, 'Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2', Journal of Clinical Oncology, vol. 11, no. 4, pp. 652-660. https://doi.org/10.1200/JCO.1993.11.4.652
Curti, B. D. ; Longo, D. L. ; Ochoa, A. C. ; Conlon, K. C. ; Smith, J. W. ; Alvord, W. G. ; Creekmore, S. P. ; Fenton, R. G. ; Gause, B. L. ; Holmlund, J. ; Janik, J. E. ; Ochoa, J. ; Rice, P. A. ; Sharfman, W. H. ; Sznol, M. ; Urba, W. J. / Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 4. pp. 652-660.
@article{738d28e324064e5e915220298541c9d7,
title = "Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2",
abstract = "Purpose: This study describes the physiologic and biologic effects resulting from the adoptive transfer of ex vivo anti-CD3-stimulated T-killer cells (T-AK) to patients with advanced cancer in combination with interleukin-2 (IL-2). Methods: Autologous peripheral-blood mononuclear cells were obtained by leukapheresis and stimulated ex vivo with anti-CD3. The stimulated cells were reinfused at one of three dose levels on the next day (5 x 109, 7.5 x 109, and 1 x 1010). Cell administration was followed by IL-2 given by bolus and continuous infusion (1.5 x 106 U/m2 and 3.0 x 106 U/m2, respectively) for 7 days, or continuous infusion alone (3.0 x 106 U/m2) for 14 days. Results: Pronounced leukocytosis and atypical lymphocytosis were observed with individual values as high as 80,000 and 50,000 cells/μL, respectively. The other major clinical sequelae included a marked lactic acidosis with bicarbonate levels as low as 4.0 mmol/L in some patients, and prolongation of the prothrombin time (PT) and partial thromboplastin time (PTT) due to decreases in clotting factors VII, IX, and X. Antithrombin III levels were also reduced. Hypotension associated with increased serum nitrate and neopterin levels was observed. These toxicities were accompanied by increases in hepatocellular enzymes and creatinine previously described with IL-2. These events occurred at a time when the number of circulating T-AK cells reached their peak. The amount of bolus IL- 2 correlated with increases in WBC count (P = .0311), atypical lymphocytes (P = .0241), PT (P = .0006), and PTT (P = .0122). Conclusion: Substantial in vivo expansion of activated T lymphocytes was induced by a protocol combining ex vivo activation of peripheral-blood cells with anti-CD3 antibody followed by adoptive transfer and IL-2 administration. The synchronous expansion of these T cells superimposed on diminished liver and kidney function from IL-2 can cause profound but reversible metabolic changes.",
author = "Curti, {B. D.} and Longo, {D. L.} and Ochoa, {A. C.} and Conlon, {K. C.} and Smith, {J. W.} and Alvord, {W. G.} and Creekmore, {S. P.} and Fenton, {R. G.} and Gause, {B. L.} and J. Holmlund and Janik, {J. E.} and J. Ochoa and Rice, {P. A.} and Sharfman, {W. H.} and M. Sznol and Urba, {W. J.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.4.652",
language = "English (US)",
volume = "11",
pages = "652--660",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2

AU - Curti, B. D.

AU - Longo, D. L.

AU - Ochoa, A. C.

AU - Conlon, K. C.

AU - Smith, J. W.

AU - Alvord, W. G.

AU - Creekmore, S. P.

AU - Fenton, R. G.

AU - Gause, B. L.

AU - Holmlund, J.

AU - Janik, J. E.

AU - Ochoa, J.

AU - Rice, P. A.

AU - Sharfman, W. H.

AU - Sznol, M.

AU - Urba, W. J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: This study describes the physiologic and biologic effects resulting from the adoptive transfer of ex vivo anti-CD3-stimulated T-killer cells (T-AK) to patients with advanced cancer in combination with interleukin-2 (IL-2). Methods: Autologous peripheral-blood mononuclear cells were obtained by leukapheresis and stimulated ex vivo with anti-CD3. The stimulated cells were reinfused at one of three dose levels on the next day (5 x 109, 7.5 x 109, and 1 x 1010). Cell administration was followed by IL-2 given by bolus and continuous infusion (1.5 x 106 U/m2 and 3.0 x 106 U/m2, respectively) for 7 days, or continuous infusion alone (3.0 x 106 U/m2) for 14 days. Results: Pronounced leukocytosis and atypical lymphocytosis were observed with individual values as high as 80,000 and 50,000 cells/μL, respectively. The other major clinical sequelae included a marked lactic acidosis with bicarbonate levels as low as 4.0 mmol/L in some patients, and prolongation of the prothrombin time (PT) and partial thromboplastin time (PTT) due to decreases in clotting factors VII, IX, and X. Antithrombin III levels were also reduced. Hypotension associated with increased serum nitrate and neopterin levels was observed. These toxicities were accompanied by increases in hepatocellular enzymes and creatinine previously described with IL-2. These events occurred at a time when the number of circulating T-AK cells reached their peak. The amount of bolus IL- 2 correlated with increases in WBC count (P = .0311), atypical lymphocytes (P = .0241), PT (P = .0006), and PTT (P = .0122). Conclusion: Substantial in vivo expansion of activated T lymphocytes was induced by a protocol combining ex vivo activation of peripheral-blood cells with anti-CD3 antibody followed by adoptive transfer and IL-2 administration. The synchronous expansion of these T cells superimposed on diminished liver and kidney function from IL-2 can cause profound but reversible metabolic changes.

AB - Purpose: This study describes the physiologic and biologic effects resulting from the adoptive transfer of ex vivo anti-CD3-stimulated T-killer cells (T-AK) to patients with advanced cancer in combination with interleukin-2 (IL-2). Methods: Autologous peripheral-blood mononuclear cells were obtained by leukapheresis and stimulated ex vivo with anti-CD3. The stimulated cells were reinfused at one of three dose levels on the next day (5 x 109, 7.5 x 109, and 1 x 1010). Cell administration was followed by IL-2 given by bolus and continuous infusion (1.5 x 106 U/m2 and 3.0 x 106 U/m2, respectively) for 7 days, or continuous infusion alone (3.0 x 106 U/m2) for 14 days. Results: Pronounced leukocytosis and atypical lymphocytosis were observed with individual values as high as 80,000 and 50,000 cells/μL, respectively. The other major clinical sequelae included a marked lactic acidosis with bicarbonate levels as low as 4.0 mmol/L in some patients, and prolongation of the prothrombin time (PT) and partial thromboplastin time (PTT) due to decreases in clotting factors VII, IX, and X. Antithrombin III levels were also reduced. Hypotension associated with increased serum nitrate and neopterin levels was observed. These toxicities were accompanied by increases in hepatocellular enzymes and creatinine previously described with IL-2. These events occurred at a time when the number of circulating T-AK cells reached their peak. The amount of bolus IL- 2 correlated with increases in WBC count (P = .0311), atypical lymphocytes (P = .0241), PT (P = .0006), and PTT (P = .0122). Conclusion: Substantial in vivo expansion of activated T lymphocytes was induced by a protocol combining ex vivo activation of peripheral-blood cells with anti-CD3 antibody followed by adoptive transfer and IL-2 administration. The synchronous expansion of these T cells superimposed on diminished liver and kidney function from IL-2 can cause profound but reversible metabolic changes.

UR - http://www.scopus.com/inward/record.url?scp=0027462552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027462552&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.4.652

DO - 10.1200/JCO.1993.11.4.652

M3 - Article

C2 - 8257476

AN - SCOPUS:0027462552

VL - 11

SP - 652

EP - 660

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -